Pfizer Announces Top-Line Results From JADE TEEN Trial Of Abrocitinib In Adolescents With Moderate-To-Severe Atopic Dermatitis; Observed Improvements In Skin Clearance, Disease Extent, And Severity Among Patients 12 To <18